Ciprofloxacin in acute male gonorrhea
Abstract:
100 male adults suffering from acute gonococcal urethritis were hospitalised and treated with decreasing doses from 2000 mg to 100 mg of ciprofloxacin (1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid, Bay o 9867; designated tradename: Ciprobay). Clinical signs (burning, exudate, edema, inflammation) and bacteriology (native and culture) were assessed hourly during the first 9 h and at 12, 24 and 72 h after start of therapy. Most patients were controlled during 10 days. 99 patients showed clinical and bacteriological cure. One patient with subacute gonococcal urethritis (protocol violation) did not react on 250 mg. No postgonococcal urethritis was seen. No side effects were reported. For the acute male gonococcal urethritis a 100 mg single dose treatment with ciprofloxacin can be recommended.
More Related Videos
07:28Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
Published on: October 29, 2020
07:39Longitudinal Follow-Up of Urinary Tract Infections and Their Treatment in Mice using Bioluminescence Imaging
Published on: June 14, 2021
Related Concept Videos
Sexually Transmitted Infections
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis I: Introduction
Acute Pyelonephritis II: Diagnostic Studies and Management
Trichomoniasis
Inhibitors of Bacterial DNA Synthesis
